MDX2001 not checked
ModeX Therapeutics, An OPKO Health Company
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “MDX2001 intravenous infusion or subcutaneous (SC) injection.”In the company’s words, NCT06239194 on ClinicalTrials.gov
- Tested for
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer and 13 more
- Main trialPhase 1/2
- “This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.”In the company’s words, NCT06239194 on ClinicalTrials.gov
Other drugs for Biliary Tract Cancer
- Trastuzumab deruxtecanDaiichi Sankyo · AstraZeneca · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- CTX-009Compass Therapeutics · Phase 2/3
- RilvegostomigAstraZeneca · Phase 3
- NanvuranlatJ-Pharma Co., Ltd. · Phase 3
- DurvalumabAstraZeneca · Phase 3
Coming up1
- Aug 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Aug 2028 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026